• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Low Vision Rehabilitation Referral Characteristics for Patients with Neovascular Age-Related Macular Degeneration.新生血管性年龄相关性黄斑变性患者的低视力康复转诊特征
Healthcare (Basel). 2025 Jan 1;13(1):64. doi: 10.3390/healthcare13010064.
2
Low Vision Services Are Underutilized by Patients with Vision Loss from Corneal Disease.角膜疾病导致视力丧失的患者对低视力服务的利用率较低。
Cornea. 2025 Mar 11. doi: 10.1097/ICO.0000000000003847.
3
Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults: EDNA diagnostic accuracy study.老年人群中未受影响的第二眼新生血管性黄斑变性的早期无创性检测:EDNA 诊断准确性研究。
Health Technol Assess. 2022 Jan;26(8):1-142. doi: 10.3310/VLFL1739.
4
Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.维替泊芬光动力疗法队列研究:报告3:成本效益及对未来评估的启示
Ophthalmology. 2009 Dec;116(12):2471-77.e1-2. doi: 10.1016/j.ophtha.2009.10.023.
5
Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK.维替泊芬光动力疗法治疗新生血管性年龄相关性黄斑变性:英国队列研究。
Health Technol Assess. 2012;16(6):i-xii, 1-200. doi: 10.3310/hta16060.
6
A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).一项评估抑制年龄相关性脉络膜新生血管(IVAN)中血管内皮生长因子(VEGF)替代治疗的临床有效性和成本效益的随机对照试验。
Health Technol Assess. 2015 Oct;19(78):1-298. doi: 10.3310/hta19780.
7
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.真实世界中抗 VEGF 药物治疗新生血管性年龄相关性黄斑变性的疗效和成本效果分析:真实世界研究的系统评价和荟萃分析。
Adv Ther. 2020 Jan;37(1):300-315. doi: 10.1007/s12325-019-01147-6. Epub 2019 Nov 14.
8
Barriers to Low-Vision Rehabilitation Services for Visually Impaired Patients in a Multidisciplinary Ophthalmology Outpatient Practice.多学科眼科门诊中视力受损患者低视力康复服务的障碍
J Ophthalmol. 2021 Nov 29;2021:6122246. doi: 10.1155/2021/6122246. eCollection 2021.
9
Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.雷珠单抗用于新生血管性年龄相关性黄斑变性的港口分娩系统的成本效用分析。
Ophthalmol Retina. 2024 May;8(5):431-446. doi: 10.1016/j.oret.2023.11.002. Epub 2023 Nov 21.
10
The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.在视力良好的新生血管性年龄相关性黄斑变性(neovascular AMD)眼中启动雷珠单抗治疗的成本效益:一项使用真实世界结果的经济模型。
BMJ Open. 2015 May 5;5(5):e006535. doi: 10.1136/bmjopen-2014-006535.

本文引用的文献

1
Age-Related Macular Degeneration: An Exponentially Emerging Imminent Threat of Visual Impairment and Irreversible Blindness.年龄相关性黄斑变性:一种视觉障碍和不可逆失明的指数级增长的迫在眉睫的威胁。
Cureus. 2023 May 29;15(5):e39624. doi: 10.7759/cureus.39624. eCollection 2023 May.
2
Low Vision Rehabilitation Service Utilization Before and After Implementation of a Clinical Decision Support System in Ophthalmology.眼科临床决策支持系统实施前后低视力康复服务利用情况
JAMA Netw Open. 2023 Feb 1;6(2):e2254006. doi: 10.1001/jamanetworkopen.2022.54006.
3
Barriers and facilitators in the referral pathways to low vision services from the perspective of patients and professionals: a qualitative study.从患者和专业人员的角度来看,低视力服务转诊途径中的障碍和促进因素:一项定性研究。
BMC Health Serv Res. 2023 Jan 21;23(1):64. doi: 10.1186/s12913-022-09003-0.
4
Vision Rehabilitation Preferred Practice Pattern®.视力康复首选实践模式®
Ophthalmology. 2023 Mar;130(3):P271-P335. doi: 10.1016/j.ophtha.2022.10.033. Epub 2022 Dec 19.
5
Low Vision Referral Patterns in Intermediate Age-Related Macular Degeneration.中老年黄斑变性患者的低视力转诊模式。
Curr Eye Res. 2022 Dec;47(12):1641-1645. doi: 10.1080/02713683.2022.2135104. Epub 2022 Oct 19.
6
Mental health and visual acuity in patients with age-related macular degeneration.年龄相关性黄斑变性患者的心理健康和视力。
BMC Ophthalmol. 2022 Oct 2;22(1):391. doi: 10.1186/s12886-022-02602-9.
7
Addressing Social Determinants of Vision Health.应对视力健康的社会决定因素。
Ophthalmol Ther. 2022 Aug;11(4):1371-1382. doi: 10.1007/s40123-022-00531-w. Epub 2022 Jun 8.
8
Utilization of Remote Diabetic Retinal Screening in a Suburban Healthcare System.郊区医疗系统中远程糖尿病视网膜筛查的应用
Clin Ophthalmol. 2021 Sep 21;15:3865-3875. doi: 10.2147/OPTH.S330913. eCollection 2021.
9
Association Between Visual Impairment and Depression in Patients Attending Eye Clinics: A Meta-analysis.就诊于眼科诊所的患者的视力障碍与抑郁之间的关联:一项荟萃分析。
JAMA Ophthalmol. 2021 Jul 1;139(7):753-761. doi: 10.1001/jamaophthalmol.2021.1557.
10
Developing an Ophthalmology Clinical Decision Support System to Identify Patients for Low Vision Rehabilitation.开发眼科临床决策支持系统,以识别需要进行低视力康复的患者。
Transl Vis Sci Technol. 2021 Mar 1;10(3):24. doi: 10.1167/tvst.10.3.24.

新生血管性年龄相关性黄斑变性患者的低视力康复转诊特征

Low Vision Rehabilitation Referral Characteristics for Patients with Neovascular Age-Related Macular Degeneration.

作者信息

Archambault Simon D, Sweeny Courtney, Bhardwaj Mahesh, Ramsey David J

机构信息

Division of Ophthalmology, Department of Surgery, UMass Chan-Lahey School of Medicine, Burlington, MA 01805, USA.

Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA.

出版信息

Healthcare (Basel). 2025 Jan 1;13(1):64. doi: 10.3390/healthcare13010064.

DOI:10.3390/healthcare13010064
PMID:39791671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11720129/
Abstract

: Despite evidence that low vision rehabilitation (LVR) services can improve visual function in patients with neovascular age-related macular degeneration (nAMD), many patients are not directed to access these resources. This study was conducted to determine factors associated with LVR referral and to assess the visual outcomes from completed evaluations. : The study comprised a retrospective, cross-sectional analysis of patients with nAMD. Referrals for LVR services were extracted from the electronic health record (EHR). The effectiveness of each evaluation was determined by assessing the change in best corrected visual acuity (BCVA) achieved after distance refraction. Costs, quality-adjusted life years (QALYs), and incremental costs per-QALY-gained were calculated based upon the better-seeing eye by using a willingness-to-pay threshold of $50,000/QALY. : Out of 560 eligible patients with nAMD, 110 were referred for LVR (19.6%). Referral was more common for individuals who qualified as having low vision, based upon the visual acuity of the better-seeing eye (adjusted odds ratio [aOR], 3.214; 95% confidence interval [CI], 1.920-5.380, < 0.001), had bilateral nAMD (aOR, 1.592; 95% CI, 1.017-2.492, = 0.042), or had commercial health insurance compared to those who had Medicare (aOR, 2.887; 95% CI, 1.041-8.009, = 0.042). Most patients referred completed LVR appointments (86%). More than half of the patients achieved improved BCVA for their better-seeing eye (53%) yielding an average gain of 0.04 QALYs/patient at a cost of $3504/QALY. The estimated net monetary benefit was $1704 per evaluation completed. : Most patients with nAMD achieved improvements in visual function after low vision evaluation, yielding improvements in vision-related quality of life at a reasonable cost.

摘要

尽管有证据表明低视力康复(LVR)服务可改善新生血管性年龄相关性黄斑变性(nAMD)患者的视觉功能,但许多患者并未被引导去获取这些资源。本研究旨在确定与LVR转诊相关的因素,并评估已完成评估的视觉结果。

该研究包括对nAMD患者进行回顾性横断面分析。从电子健康记录(EHR)中提取LVR服务的转诊信息。通过评估远距离验光后最佳矫正视力(BCVA)的变化来确定每次评估的有效性。使用每质量调整生命年(QALY)50,000美元的支付意愿阈值,根据视力较好的眼睛计算成本、QALY和每获得一个QALY的增量成本。

在560例符合条件的nAMD患者中,110例被转诊接受LVR(19.6%)。根据视力较好眼睛的视力,被认定为低视力的个体转诊更为常见(调整优势比[aOR],3.214;95%置信区间[CI],1.920 - 5.380,P < 0.001),患有双侧nAMD(aOR,1.592;95% CI,1.017 - 2.492,P = 0.042),或与拥有医疗保险的患者相比拥有商业健康保险(aOR,2.887;95% CI,1.041 - 8.009,P = 0.042)。大多数被转诊的患者完成了LVR预约(86%)。超过一半的患者视力较好的眼睛的BCVA得到改善(53%),每位患者平均获得0.04个QALY,成本为每QALY 3504美元。每次完成的评估估计净货币收益为1704美元。

大多数nAMD患者在低视力评估后视觉功能得到改善,以合理的成本改善了与视力相关的生活质量。